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Abstract
Background: Causative variants in BRCA1 and BRCA2 are well-established risk factors for breast and ovarian cancer. In
Poland, the causative founder variants in the BRCA1 are responsible for a significant proportion of ovarian cancer cases,
however, regional differences in the frequencies of various mutations may exist. The spectrum and frequency of
BRCA1/2 mutations between ovarian cancer patients have not yet been studied in the region of South-East Poland.
Methods: We examined 158 consecutive unselected cases of ovarian cancer patients from the region of Podkarpacie.
We studied 13 Polish causative founder variants in BRCA1 (c.5266dupC, c.4035delA, c.5251C > T, c.181 T > G, c.676delT,
c.68_69delAG, c.3700_3704delGTAAA, c.1687C > T, c.3756_3759delGTCT) and in BRCA2 (c.658_659delGT, c.7910_
7914delCCTTT, c.3847_3848delGT, c.5946delT).
Results: A BRCA1 causative founder variants were detected in 10 of the 158 (6.3%) ovarian cancer cases.
BRCA2 causative founder variants were not observed. The c.5266dupC mutation was detected in 6 patients, c.
181 T > G mutation in 3 patients and the c.676delT mutation in 1 patient. The median age of diagnosis of
the 10 hereditary ovarian cancers was 55.5 years of age.
Conclusions: The frequency of 13 causative founder variants in Podkarpacie was lower than in other regions of Poland.
Testing of three BRCA1 mutations (c.5266dupC, c.181 T > G, c.676delT) should be considered a sensitive test panel.
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Background
There are approximately 3600 new ovarian cancer cases
and over 2000 deaths as a result of this cancer in Poland
annually [1]. It has been shown that ovarian cancer patients
from Poland are characterized by a high proportion of a
limited number of recurrent mutations in BRCA1 [2–7].
Three BRCA1 causative founder variants (c.5266dupC,
c.181 T >G, and c.4035delA) account for approximately
80% of all detectable BRCA1 and BRCA2 mutations in
breast-ovarian cancer families in Poland [2, 3]. A high pro-
portion of BRCA-carriers with a limited number of recur-
rent mutations have an impact on the test costs reduction,
it enhances the availability and testing effectiveness. In
2003, Menkiszak et al. observed that 13.5% of ovarian can-
cer patients in the Szczecin region carry one of these three
common causative founder variants in BRCA1 [8]. Since
2003, several other less frequent recurrent BRCA1 and
BRCA2 mutations have been reported as well as some re-
gional differences in mutation frequency and spectrum
have been observed [2–8]. Currently, five BRCA1 causative
founder variants (c.5266dupC, c.181 T >G, and c.4035delA,
c.68_69delAG, c.3700_3704delGTAAA) are recommended
in national screening program.
The aim of this study was to evaluate the prevalence
and spectrum of 13 BRCA1 and BRCA2 causative
founder variants in unselected patients diagnosed with
ovarian cancer from Region of Podkarpacie. These ob-
servations may be important to optimize the genetic
testing strategy for ovarian cancer patients in the region.
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Methods
The ovarian cancer cases were identified among clinical
base patients of the Department of Obstetrics and
Gynecology of Fryderyk Chopin University Hospital No
1 in Rzeszów, Poland between January 2013 and January
2017. All patients were inhabitants of the South-East re-
gion of Poland. The study group consisted of 158 con-
secutive, newly diagnosed cases of ovarian cancer after
surgical treatment, unselected based on age or family
history. The mean age of diagnosis was 58.5 years (range
22–84 years). The reference pathologist reviewed a rep-
resentative slide from each cancer to confirm the diag-
nosis. 20% of patients were diagnosed in I and II clinical
stage and 80% in III and IV according to FIGO. 14.8% of
ovarian cancers showed pathological grading G1, 11.1% -
G2, and 74.1% – G3. A cancer family history was ob-
tained during an appointment with clinical geneticist.
DNA was isolated from 5 to 10 ml of blood. All
women were tested for the presence of 13 causative
founder variants in BRCA1 (nine mutations) and BRCA2
(four mutations). The c.4035delA and c.5266dupC muta-
tions were detected using allele-specific oligonucleotide
polymerase chain reaction (PCR) [7]. The other muta-
tions of BRCA1 (c.5251C > T, c.181 T > G, c.676delT,
c.68_69delAG, c.3700_3704delGTAAA, c.1687C > T,
c.3756_3759delGTCT) and in BRCA2 (c.658_659delGT,
c.7910_7914delCCTTT, c.3847_3848delGT, c.5946delT)
were genotyped using TaqMan assays (Applied Biosys-
tems/Life Technologies, Carlsbad, CA) on Roche Light-
Cycler 480. All mutations were confirmed by Sanger
direct sequencing. Sequencing reactions were performed
using a BigDye Terminator v3.1 Cycle Sequencing Kit
(Life Technologies) according to the manufacturer’s
protocol. Sequencing products were analyzed on the ABI
Prism 3100 Genetic Analyzer (Life Technologies).
Results
A BRCA1 causative founder variants were detected in 10 of
the 158 (6.3%) unselected ovarian cancer cases. The
c.5266dupC mutation was the most common, having been
diagnosed in six patients, followed by the c.181 T >G mu-
tation observed in three patients and the c.676delT muta-
tion in one patient (Table 1). The median age of diagnosis
of the 10 hereditary ovarian cancers patients was 55.5 years
(range 41–82 years), compared with a median age of diag-
nosis of 58.75 years (range 22–84 years) for the 148 cases
without a mutation. A mutation was found in 9.7% (3/31)
of women diagnosed with ovarian cancer at or under the
age of 50 compared to 5.5% (7/127) of women diagnosed at
a later age. Among the 10 women with ovarian cancer and
a BRCA1 mutation, six reported a first- or second-degree
relative with breast or ovarian cancer (60%). A mutation
was present in 15.4% (6/39) of ovarian cancer patients with
a positive family history and in 3.4% (4/119) of women with
a negative family history. A significant family history, de-
fined as a presence of first- or second-degree relative with
breast or ovarian cancer, was observed in 24.7% (39/158) of
patients with ovarian cancer (Table 2).
Discussion
The Podkarpacie region is located in the South-Eastern
part of Poland, bordered by Ukraine and Slovakia. We
found that 6.3% of unselected cases of ovarian cancer in
this region carried one of 13 causative founder variants
in the BRCA1 or BRCA2. This is a lower rate than in
other regions of Poland, where the frequency of BRCA1
causative founder variants was observed in about 10–
13.5% of ovarian cancer patients [2–8]. The frequency is,
however, high enough to support genetic testing for all
ovarian cancer patients in the region.
Since Podkarpacie is on a boundary region of Poland
next to Ukraine, it is possible that the population slightly
differs from other regions of Poland in terms of genetic
makeup. In the nineteenth century, the region was part of
Habsburg empire with significant minorities of Ukrainians
and Jews, as well as a small proportion of Germans,
Austrians, Hungarians and Armenians. Recently, Goro-
detska et al. observed a slightly lower frequency of
c.5266dupC and c.181 T >G BRCA1 mutations in a series
of ovarian cancer patients from Ukraine as compared to
other Slavic populations [9–16]. Genetic testing of BRCA1
mutations has been in place in the region since 2000. Sev-
eral hundred mutation carriers have been diagnosed and a
significant number of prophylactic oophorectomies have
been performed. It may also, to some extent, affect the
lower frequency of detected mutations than previously ob-
served in other regions.
Table 1 The frequency of causative founder variants in unselected
series of ovarian cancer patients
BRCA1 causative variant Number Percent
c.5266dupC 6 3.8
c.181 T > G 3 1.9
c.676delT 1 0.6
Table 2 Prevalence of BRCA1 causative variants in ovarian cancer
by age of onset and family history
Number
of cases
Number with
a mutation
Proportion with
a mutation (%)
Age group
≤ 50 31 3 9.7
> 50 127 7 5.5
Family history
Positive 39 6 15.4
Negative 119 4 3.4
All cases together 158 10 6.3
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Our study was limited to screening for only 13 causative
founder variants in BRCA1/2 and possibly other mutations
will be detected with whole BRCA1/2 genes sequencing. In
this study, the spectrum of detected BRCA1 mutations was
similar to the rest of Poland and to other Slavic countries
[9–16]. We observed the BRCA1 c.5266dupC mutation in
60% of carriers and the BRCA1 c.181 T >G mutation in
30% of carriers. In one case, the BRCA1 c.676delT muta-
tion was detected. This mutation is rare in Polish popula-
tion but should be included in the panel of recurrent
mutations in the screening tests. Among the familial breast
and ovarian cancers from this region, we also observed a
higher frequency of the c.68_69delAG BRCA1 mutation
(data not shown), but this mutation was not observed in
this series of consecutive ovarian cancers.
The mean age of diagnosis of the 10 cases with BRCA1
mutations was 55.5 years, which is slightly higher than
the mean age observed in other regions of Poland [6–8].
Possibly there are lifestyle/environmental factors which
may influence later age of diagnosis, however, for non-
carriers, the mean age of diagnosis was similar in Pod-
karpacie and in the rest of Poland (58.75 vs. 56.2–
62.3 years) [6–8].
A strong breast or ovarian cancer family history was
reported by 24.7% of ovarian cancer patients. It is
significantly more frequent than observed by other au-
thors [6, 8]. We think that this phenomenon may be
caused by a larger number of family members than in
other regions of Poland. Urbanization in this region used
to be lower and fertility rate higher. We observed strong
cancer family history in 6 out of 10 mutation carriers,
which is more frequent than observed in other regions
[6–8]. It can be explained by a relatively larger number
of family members. However, between familial cases as
well as between all patients with ovarian cancer we ob-
served the lower frequency of mutation carriers, there-
fore we think that we could have missed some
mutations while testing only causative founder variants.
There are several limitations to our study. The number
of cases is relatively small and the results are based on
10 mutation-positive ovarian cancer cases. The increase
of the study group was not possible because the registry
of unselected, consecutive ovarian cancer patients was
organized in 2013, and other hospitals did not create
such a registry. Due to the high mortality of patients
with ovarian cancer, a retrospective study based on a
group diagnosed before 2013 may be biased. We
screened only for the limited number of recurrent muta-
tions and it is possible that other rare mutations were
missed. Since the frequency of BRCA-carriers was sig-
nificantly lower, including cases with family history of
breast or ovarian cancer, than in other regions, the study
based on sequencing of whole BRCA1 and BRCA2
should be performed.
Conclusions
Approximately 6% of unselected ovarian cancer pa-
tients in the region of Podkarpacie Poland carry a
BRCA1 causative founder variants. These causative
variants frequency was significantly lower than in
other regions of Poland but it is sufficiently high to
support the recommendation that all ovarian cancer
patients undergo genetic testing regardless of the age
of diagnosis or family history.
Abbreviation
PCR: Polymerase chain reaction
Acknowledgements
Authors thank to Stanisława Pasternak, Małgorzata Drozd, Renata Gibaszek
and Lidia Jabłońska for excellent assistance in material and data collection.
Authors thank for support to Breast Cancer Campaign Estée Lauder
Companies.
Funding
Not applicable.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
TK the study design, database management, sample collection and computing
results, writing manuscript; AJ sample collection, the manuscript review and
approval; EM data collection, the manuscript review and approval; RJ data
collection, the manuscript review and approval; JL the study design, molecular
analysis, the manuscript review and approval; SN the study design, the
manuscript review and approval, JG: the study design, database management,
sample collection and computing results, molecular analysis, writing
manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All participants gave informed written consent prior blood donating. The
study was approved by Ethics Committee of the Pomeranian Medical
University in Szczecin, Poland (decision No. BN-001/174/05.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Obstetrics and Gynecology, Fryderyk Chopin University
Hospital No 1, Faculty of Medicine of Rzeszow University, 2 Szopena St,
35-055 Rzeszów, Poland. 2Subcarpatian Oncological Hospital, Genetic
Counseling Center, 18 Bielawskiego St, 36-200 Brzozów, Poland. 3Department
of Oncological Surgery, Regional Oncology Center, 11 Garncarska St, 31-115
Kraków, Poland. 4Deptartment of Gynecology and Obstetetrics, Medical
College, Jagiellonian University, 23 Kopernika St, 31-501 Krakow, Poland.
5Department of Genetics and Pathology, International Hereditary Cancer
Center, Pomeranian Medical University, Połabska 4 St, 70-115 Szczecin,
Poland. 6Women’s College Research Institute, 76 Grenville St, Toronto, ON
M5G 1N8, Canada.
Kluz et al. Hereditary Cancer in Clinical Practice  (2018) 16:6 Page 3 of 4
Received: 8 November 2017 Accepted: 21 February 2018
References
1. Wojciechowska U, Didkowska J, Zatoński W. Cancer. Poland: National Cancer
Registy; 2008. http://onkologia.org.pl/wp-content/uploads/Nowotwory2008.pdf
2. Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, et al.
Founder mutations in the BRCA1 gene in polish families with breast–ovarian
cancer. Am J Hum Genet. 2000;66(6):1963–8.
3. Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al.
A high proportion of founder BRCA1 mutations in polish breast and ovarian
cancer families. Int J Cancer. 2004;110:683–6.
4. Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D,
Skotnicki P, et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the
population of breast and ovarian cancer patients in southern Poland. Hered
Cancer Clin Pract. 2016;14:5.
5. Gaj P, Kluska A, Nowakowska D, Bałabas A, Piątkowska M, Dabrowska M,
et al. High frequency of BRCA1 founder mutations in polish women with
nonfamilial breast cancer. Familial Cancer. 2012;11(4):623–8.
6. Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, et al.
High frequency of BRCA1/2 germline mutations in consecutive ovarian
cancer patients in Poland. Gynecol Oncol. 2008;108(2):433–7.
7. Ratajska M, Krygier M, Stukan M, Kuźniacka A, Koczkowska M, Dudziak M,
et al. Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian
cancer patients. Novel and recurrent BRCA1/2 alterations detected by next
generation sequencing. J Appl Genet. 2015;56(2):193–8.
8. Menkiszak J, Gronwald J, Górski B, Jakubowska A, Huzarski T, Byrski T, et al.
Hereditary ovarian cancer in Poland. Int J Cancer. 2003;106(6):942–5.
9. Gorodetska I, Serga S, Lahuta T, Ostapchenko L, Demydov S, Khranovska
N, Skachkova O, Inomistova M, Kolesnik O, Svintsitsky V, Tsip N, Peresunko
A, Kmit’ N, Manzhura O, Rossokha Z, Popova O, Salomakhina H,
Kyriachenko S, Kozeretska I. Prevalence of two BRCA1 mutations, 5382insC
and 300T > G, in ovarian cancer patients from Ukraine. Familial Cancer.
2017;11 https://doi.org/10.1007/s10689-017-9978-9. [Epub ahead of print]
10. Oszurek O, Gorski B, Gronwald J, Prosolow Z, Uglanica K, Murinow A, et al.
Founder mutations in the BRCA1 gene in west Belarusian breast–ovarian
cancer families. Clin Genet. 2001;60:470–1.
11. Uglanitsa N, Oszurek O, Uglanitsa K, Savonievich E, Lubiński J, Cybulski C,
et al. The contribution of founder mutations in BRCA1 to breast cancer in
Belarus. Clin Genet. 2010;78(4):377–80.
12. Bogdanova N, Antonenkova NN, Rogov YI, Karstens JH, Hillemanns P, Dörk
T. High frequency and allele-specific differences of BRCA1 founder
mutations in breast cancer and ovarian cancer patients from Belarus. Clin
Genet. 2010;78(4):364–72.
13. Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG,
Chekmariova EV, et al. High frequency of BRCA1 5382insC mutation in
Russian breast cancer patients. Eur J Cancer. 2006;42:1380–4.
14. Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, et al. High
proportion of recurrent germ line mutations in the BRCA1 gene in breast and
ovarian cancer patients from the Prague area. Breast Cancer Res. 2005;7:R728–36.
15. Krajc M, Teugels E, Zgajnar J, Goelen G, Besic N, Novakovic S, et al. Five
recurrent BRCA1/2 mutations are responsible for cancer predisposition in
the majority of Slovenian breast cancer families. BMC Med Genet. 2008;9:83.
16. Konecny M, Milly M, Zavodna K, Weismanova E, Gregorova J, Mlkva I, et al.
Comprehensive genetic characterization of hereditary breast/ovarian cancer
families from Slovakia. Breast Cancer Res Treat. 2011;126(1):119–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kluz et al. Hereditary Cancer in Clinical Practice  (2018) 16:6 Page 4 of 4
